FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908052983> ?p ?o ?g. }

• W2908052983 endingPage "e13741" @default.
• W2908052983 startingPage "e13741" @default.
• W2908052983 abstract "Abstract Mantle cell lymphoma (MCL) is an invasive B-cell lymphoma with significant individual differences. Currently, MCL international prognostic index (MIPI) score and tumor cell proliferation index Ki-67 have been proved to be the most important prognostic factors. But the prognostic effect of these factors in Asian population is uncertain. This study aimed to analyze the disease characteristics and prognostic factors of Chinese MCL patients. A total of 83 cases of newly-diagnosed MCL patients diagnosed by the Department of Pathology of our hospital between January 1, 2011, and May 31, 2016, were enrolled. The disease characteristics, treatment effects, and outcomes of the patients were collected and analyzed. According to our analysis, MCL cases accounted for 6.2% of non-Hodgkin lymphoma (NHL) cases and mainly occurred in elderly males. But the proportion of patients at stage IV by Ann Arbor staging system and high-risk group by simplified-MIPI (s-MIPI) were significantly lower than that among European patients. Immunochemotherapy containing rituximab was significantly more effective than chemotherapy (overall response rate, [ORR]: 88.5% vs 65.2%, P = .021) and significantly prolonged patient survival (progression free survival [PFS]: 45.5 m vs 16.2 m, P = .001; overall survival [OS]: 58.3 m vs 22.8 m, P = .001). The multivariate analysis showed that the B symptoms, s-MIPI and administration of immunochemotherapy were independent prognostic factors that affected PFS and OS of the patients. s-MIPI and B symptom make up s-MIPI-B stratification method, by which patients in low-risk group of s-MIPI without B symptom were classified as low-risk, patients in high-risk group of s-MIPI and patients in low-risk group of s-MIPI with B symptom as high-risk, the rest as middle-risk. 3-year PFS of the 3 groups were 74.9%, 43.4% and 16.1%, respectively ( P = .001). 3-year OS were 84.4%, 62.2%, 27.6% ( P <.001). Chinese MCL was male predominance. We have a minor proportion of late-stage and high-risk patients compared to European patients. Immunochemotherapy was proved to significantly improve the prognosis of MCL patients. B symptoms, s-MIPI, and administration of rituximab independently influenced the outcome. s-MIPI-B prognostic stratification method may better predict the prognosis of Asian MCL patients. Still, further confirmation in larger populations is needed." @default.
• W2908052983 created "2019-01-11" @default.
• W2908052983 creator A5005286554 @default.
• W2908052983 creator A5018948553 @default.
• W2908052983 creator A5026150923 @default.
• W2908052983 creator A5030342643 @default.
• W2908052983 creator A5036246435 @default.
• W2908052983 creator A5051881032 @default.
• W2908052983 creator A5053294900 @default.
• W2908052983 creator A5053466470 @default.
• W2908052983 creator A5086717542 @default.
• W2908052983 creator A5089639451 @default.
• W2908052983 creator A5089986341 @default.
• W2908052983 date "2019-01-01" @default.
• W2908052983 modified "2023-10-06" @default.
• W2908052983 title "Simplified MIPI-B prognostic stratification method can predict the outcome well—retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China" @default.
• W2908052983 cites W1192491316 @default.
• W2908052983 cites W1540451276 @default.
• W2908052983 cites W1549556227 @default.
• W2908052983 cites W1829587101 @default.
• W2908052983 cites W1873594900 @default.
• W2908052983 cites W1897142399 @default.
• W2908052983 cites W1912693401 @default.
• W2908052983 cites W1982330025 @default.
• W2908052983 cites W1990464386 @default.
• W2908052983 cites W1996477426 @default.
• W2908052983 cites W2024040061 @default.
• W2908052983 cites W2029511375 @default.
• W2908052983 cites W2029940110 @default.
• W2908052983 cites W2036266060 @default.
• W2908052983 cites W2040410729 @default.
• W2908052983 cites W2041268382 @default.
• W2908052983 cites W2043275534 @default.
• W2908052983 cites W2049159227 @default.
• W2908052983 cites W2051648120 @default.
• W2908052983 cites W2056557894 @default.
• W2908052983 cites W2061316813 @default.
• W2908052983 cites W2076304345 @default.
• W2908052983 cites W2079284027 @default.
• W2908052983 cites W2092944309 @default.
• W2908052983 cites W2096672814 @default.
• W2908052983 cites W2099501131 @default.
• W2908052983 cites W2102569805 @default.
• W2908052983 cites W2125684345 @default.
• W2908052983 cites W2130669641 @default.
• W2908052983 cites W2134482296 @default.
• W2908052983 cites W2137228311 @default.
• W2908052983 cites W2151092645 @default.
• W2908052983 cites W2158945674 @default.
• W2908052983 cites W2167921754 @default.
• W2908052983 cites W2169209759 @default.
• W2908052983 cites W2184668473 @default.
• W2908052983 cites W2187899653 @default.
• W2908052983 cites W2289178667 @default.
• W2908052983 cites W2412356789 @default.
• W2908052983 cites W2430862255 @default.
• W2908052983 cites W2477374712 @default.
• W2908052983 cites W2519978100 @default.
• W2908052983 cites W2589193557 @default.
• W2908052983 cites W2605009867 @default.
• W2908052983 cites W2616164584 @default.
• W2908052983 cites W2749289906 @default.
• W2908052983 cites W3142684940 @default.
• W2908052983 cites W4376596284 @default.
• W2908052983 doi "https://doi.org/10.1097/md.0000000000013741" @default.
• W2908052983 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6344161" @default.
• W2908052983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30608386" @default.
• W2908052983 hasPublicationYear "2019" @default.
• W2908052983 type Work @default.
• W2908052983 sameAs 2908052983 @default.
• W2908052983 citedByCount "4" @default.
• W2908052983 countsByYear W29080529832020 @default.
• W2908052983 countsByYear W29080529832021 @default.
• W2908052983 countsByYear W29080529832022 @default.
• W2908052983 crossrefType "journal-article" @default.
• W2908052983 hasAuthorship W2908052983A5005286554 @default.
• W2908052983 hasAuthorship W2908052983A5018948553 @default.
• W2908052983 hasAuthorship W2908052983A5026150923 @default.
• W2908052983 hasAuthorship W2908052983A5030342643 @default.
• W2908052983 hasAuthorship W2908052983A5036246435 @default.
• W2908052983 hasAuthorship W2908052983A5051881032 @default.
• W2908052983 hasAuthorship W2908052983A5053294900 @default.
• W2908052983 hasAuthorship W2908052983A5053466470 @default.
• W2908052983 hasAuthorship W2908052983A5086717542 @default.
• W2908052983 hasAuthorship W2908052983A5089639451 @default.
• W2908052983 hasAuthorship W2908052983A5089986341 @default.
• W2908052983 hasBestOaLocation W29080529831 @default.
• W2908052983 hasConcept C126322002 @default.
• W2908052983 hasConcept C143998085 @default.
• W2908052983 hasConcept C146357865 @default.
• W2908052983 hasConcept C151730666 @default.
• W2908052983 hasConcept C167135981 @default.
• W2908052983 hasConcept C2777525834 @default.
• W2908052983 hasConcept C2778476033 @default.
• W2908052983 hasConcept C2779338263 @default.
• W2908052983 hasConcept C2780653079 @default.
• W2908052983 hasConcept C2908647359 @default.
• W2908052983 hasConcept C38180746 @default.

• next